Understanding Cognitive Deficits in Schizophrenia

Current Treatment Limitations

Current treatment approaches for schizophrenia are largely insufficient in addressing the cognitive deficits associated with the disorder. To enhance treatment efficacy, researchers from Norway are investigating the genetic factors that contribute to the risk of schizophrenia and the severity of cognitive impairments.

Overview of Schizophrenia

Schizophrenia is a chronic psychiatric disorder that affects around 1% of the global population. The development of the illness is influenced by both environmental and genetic factors. Symptoms typically emerge during or shortly after puberty, leading to significant long-term impairment and disability. These symptoms can be categorized into three main types:

– **Positive Symptoms**: These include experiences not typically present in healthy individuals, such as auditory hallucinations and delusions.
– **Negative Symptoms**: These refer to normal functions that are diminished or absent in patients, resulting in increased social isolation, apathy, and a lack of pleasure.
– **Cognitive Symptoms**: These involve impairments in attention, verbal and visual learning, emotion regulation, executive function, and memory.

While positive symptoms often respond well to conventional antipsychotic medications, current strategies fall short in alleviating negative symptoms and cognitive deficits. A deeper understanding of the mechanisms behind these cognitive issues is essential for developing improved treatment options.

Recent Research Findings

Study Overview

In a study published in JAMA Psychiatry, Norwegian researchers aimed to identify genetic loci that influence both the risk of schizophrenia and specific cognitive domains, including reaction time, verbal-numerical reasoning, and general cognitive function. Their focus was on locating shared genomic regions that link schizophrenia with cognitive dysfunction.

Between July 24, 2014, and January 17, 2017, the researchers conducted a comprehensive analysis of four extensive genome-wide datasets, including:

– Psychiatric Genomics Consortium cohort (n = 79,757)
– UK Biobank cohort (n = 36,035)
– Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) (n = 53,949)
– Cognitive Genomics Consortium (COGENT) (n = 27,888)

In total, they examined genetic data from over 250,000 participants.

Key Findings

The study identified 21 genetic loci that jointly influence schizophrenia and cognitive traits:

– 2 loci associated with verbal-numerical reasoning
– 6 loci related to reaction time
– 14 loci connected to general cognitive function

Notably, one locus was identified as the strongest shared signal between schizophrenia and two cognitive traits, specifically linked to the gene TCF20 on chromosome 22q13.3. For 18 of the genetic variants studied, an association was found between schizophrenia risk and poorer cognitive performance.

Implications of the Research

This research sheds light on the genetic underpinnings of schizophrenia, enhancing our understanding of this complex condition. The findings align with previous studies suggesting a common genetic basis for cognitive dysfunction and schizophrenia risk. By identifying specific gene variants, this research can inform future strategies aimed at developing effective treatments to reduce cognitive impairments in individuals with schizophrenia.

Reference

Kellen, D. A. (PhD). Citation: Smeland, O. B., Frei, O., Kauppi, K., Hill, W. D., Li, W., Wang, Y., … Andreassen, O. A. (2017). Identification of genetic loci jointly influencing schizophrenia risk and the cognitive traits of verbal-numerical reasoning, reaction time, and general cognitive function. JAMA Psychiatry, E1-E11. DOI: 10.1001/jamapsychiatry.2017.1986